Voyager gets $165M up front from Neurocrine for gene therapies

Voyager Therapeutics Inc. (NASDAQ:VYGR) will receive $165 million up front from Neurocrine Biosciences Inc. (NASDAQ:NBIX) in exchange for a license to four of Voyager's neurology gene

Read the full 267 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE